UTHR vs. ALNY, BIIB, NBIX, INCY, BMRN, EXAS, EXEL, RGEN, HALO, and MDGL
Should you be buying United Therapeutics stock or one of its competitors? The main competitors of United Therapeutics include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Neurocrine Biosciences (NBIX), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Exelixis (EXEL), Repligen (RGEN), Halozyme Therapeutics (HALO), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry.
United Therapeutics vs.
Alnylam Pharmaceuticals (NASDAQ:ALNY) and United Therapeutics (NASDAQ:UTHR) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, community ranking, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.
United Therapeutics has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.
Alnylam Pharmaceuticals presently has a consensus price target of $298.61, indicating a potential upside of 8.60%. United Therapeutics has a consensus price target of $382.08, indicating a potential upside of 8.15%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Alnylam Pharmaceuticals is more favorable than United Therapeutics.
93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 94.1% of United Therapeutics shares are owned by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are owned by insiders. Comparatively, 11.9% of United Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Alnylam Pharmaceuticals received 544 more outperform votes than United Therapeutics when rated by MarketBeat users. Likewise, 76.19% of users gave Alnylam Pharmaceuticals an outperform vote while only 62.50% of users gave United Therapeutics an outperform vote.
United Therapeutics has a net margin of 40.31% compared to Alnylam Pharmaceuticals' net margin of -15.86%. United Therapeutics' return on equity of 19.22% beat Alnylam Pharmaceuticals' return on equity.
In the previous week, Alnylam Pharmaceuticals had 8 more articles in the media than United Therapeutics. MarketBeat recorded 22 mentions for Alnylam Pharmaceuticals and 14 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 1.00 beat Alnylam Pharmaceuticals' score of 0.83 indicating that United Therapeutics is being referred to more favorably in the news media.
Alnylam Pharmaceuticals has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500.
Summary
United Therapeutics beats Alnylam Pharmaceuticals on 11 of the 18 factors compared between the two stocks.
Get United Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
United Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:UTHR) was last updated on 2/6/2025 by MarketBeat.com Staff